PALENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:
MYERS BIGEL SIBLEY SAJOVEC, P.A.
P.O. Box 37428
Raleigh, NC 27627
UNITED STATES OF AMERICA

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION

06-28-05 A09:00 III	(PCT Rule 44.1)		
	Date of mailing (day/month/year) 22/06/2005		
Applicant's or agent's file reference			
9336.20.WO	FOR FURTHER ACTION See paragraphs 1 and 4 below		
International application No.	International filing date		
PCT/US2004/035424	(day/month/year) 26/10/2004		
Applicant			
ORIEL THERAPEUTICS, INC.			

1. X	The applicant is hereby notified that the international search report and the written opinion of the International Searchir Authority have been established and are transmitted herewith.							
	Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):							
	When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.							
	Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes 1211 Geneva 20, Switzerland, Fascimile No.: (41-22) 740.14.35							
	For more detailed instructions, see the notes on the accompanying sheet.							
2. [The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.							
з. 🔲	With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:							
	the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.							

4. Reminders

Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fax: (+31-70) 340-3016

Authorized officer

Sylvie Fernandez

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the *PCT Applicant's Guide*, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report and the written opinion of the International Searching Authority, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims,description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only (see *PCT Applicant's Guide*, Annexes B1 and B2).

The attention of the applicant is drawn to the fact that amendments to the claims under Article 19 are not allowed where the International Searching Authority has declared, under Article 17(2), that no international search report would be established (see *PCT Applicant's Guide*, Volume I/A, paragraph 296).

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER		see Form PCT/ISA/220					
9336.20.WO	ACTION	as well	as, where applicable, item 5 below.					
International application No.	International filing date (day/month/year)		(Earliest) Priority Date (day/month/year)					
PCT/US2004/035424	26/10/2004		27/10/2003					
Applicant								
ORIEL THERAPEUTICS, INC.		and the second s						
This International Search Report has been according to Article 18. A copy is being tra	prepared by this International Sea	rching Auth J.	ority and is transmitted to the applicant					
This International Search Report consists	of a total of6sh	eets.						
It is also accompanied by	a copy of each prior art document c	ited in this	report.					
Basis of the report a. With regard to the language, the illinguage in which it was filed, unli	international search was carried out ess otherwise indicated under this it	on the bas em.	is of the international application in the					
The international this Authority (Rul		of a transla	ation of the international application furnished to					
b With regard to any nucleo	itide and/or amino acid sequence	disclosed	in the international application, see Box No. I.					
2. Certain claims were four	nd unsearchable (See Box II).							
3. X Unity of invention is lack	king (see Box III).							
4. With regard to the title,								
X the text is approved as su	bmitted by the applicant.							
the text has been establis	hed by this Authority to read as follo	ws:	`-					
			DOCKET					
			Bv_ &0 ·					
			by					
			Date 6/28					
5. With regard to the abstract,								
the text is approved as su	- ','							
the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.								
6. With regard to the drawings,								
a. the figure of the drawings to be p	ublished with the abstract is Figure	No. <u>4 A</u>						
as suggested by t		_711						
as selected by this Authority, because the applicant failed to suggest a figure. as selected by this Authority, because this figure better characterizes the invention.								
	published with the abstract.							

International application No.

INTERNATIONAL SEARCH REPORT

PCT/US2004/035424

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

Dry powder drug containment packages (25) with tab members (30) and meted dose sealed drug compartments (25d) can be used in an inhaler (10) having a flow chamber (40) with a hook member (50) that opens the drug compartments (25d) and/or a portion that flexes to vibrate the dry powder to facilitate fluidic active dispersion for inhalation.

International application No. PCT/US2004/035424

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1,2,4,5,7,9,12-17,25
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 2, 4, 5, 7, 9, 12-17, 25

None

2. claims: 3, 4, 6, 8, 21

A drug containment system wherein the tab members have a loop member (Problem: to avoid parts of the sealant material to be inhale by the patient)

3. claims: 10, 11, 18

A drug containment system wherein each tab is associated with a plurality of drug compartments (Problem: to allow combination inhalation dry powder drug delivery in operative position in an inhaler)

4. claims: 19, 20, 22-24

A drug containment system wherein the plurality of drug compartments is at least 60 (Problem: to permit the user to have a longer journey with only one package)

5. claims: 26-50, 65-74

A dry powder inhaler with vibrator, and method of operating (Problem: to prevent agglomeration fo the powder)

6. claims: 51-64

A multi-dose dry powder inhaler with a hook member (Problem: to facilitate the opening of the blister)

INTER: JONAL SEARCH REPORT

International Application No PCT/US2004/035424

A. CLASS IPC 7	SIFICATION OF SUBJECT MATTER A61J1/03 A61M15/00 B65D75	/36 B65B5/10	
According	to International Patent Classification (IPC) or to both national classifi	cation and IPC	
	SSEARCHED		
Minimum d IPC 7	locumentation searched (classification system followed by classifica A61J B65D A61M B65B 	ltion symbols)	
Documenta	ation searched other than minimum documentation to the extent that	such documents are included in the fields sea	rched
	data base consulted during the international search (name of data b	ase and, where practical, search terms used)	
C. DOCUM	IENTS CONSIDERED TO BE RELEVANT	***************************************	
Category °	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.
X	US 5 622 166 A (EISELE ET AL) 22 April 1997 (1997-04-22) column 2, line 55 - column 3, lifigures 1-7	ine 42;	1,2,4,5, 7,9, 12-17,25
Fun	ther documents are listed in the continuation of box C.	X Patent family members are listed in	annex.
° Special ca	ategories of cited documents ;	4	
"A" docume consider c	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family	
Date of the	actual completion of the international search	Date of mailing of the international search	h report
1	11 March 2005	2 2 JUN 2005	•
Name and	mailing address of the ISA European Patent Office, P.8. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Zeinstra, H	

INTERI. JONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2004/035424

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
		WO US US AU AU BR CZ	6328034 B1 258450 T 695051 B2 5251096 A 62921 B1 101992 A 9608194 A 2217672 A1 1181709 A 9703349 A3 69631419 D1 69631419 T2 0835147 A1 9801656 A2 117706 A 3574662 B2 10512788 T 974910 A 304654 A 322909 A1 115407 B1 2162717 C2 144697 A3 384225 B 2002040713 A1 9633759 A1 5921237 A 6029663 A 729272 B2 3646697 A 9710880 A 9900189 A3	11-12-2001 15-02-2004 06-08-1998 18-11-1996 30-11-2000 31-07-1998 21-07-1998 31-10-1996 13-05-1998 14-01-1998 04-03-2004 11-11-2004 15-04-1998 28-10-1998 28-10-1998 30-11-1999 06-10-2004 08-12-1998 24-10-1997 28-01-1997 28-01-1997 28-01-1999 02-03-1998 11-03-2000 11-04-2002 31-10-1996 13-07-1999 29-02-2001 01-02-2001 10-02-1998 17-08-1999 12-05-1999
		EP HU JP 2 NO NZ NZ WO	0925084 A1 9903819 A2 001507949 T 990272 A 333685 A 505722 A 9803217 A1	30-06-1999 28-03-2000 19-06-2001 22-03-1999 29-09-2000 30-03-2001 29-01-1998

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 _ _ INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION See paragraph 2 below see form PCT/ISA/220 Priority date (day/month/year) International filing date (day/month/year) International application No. 27.10.2003 26.10.2004 PCT/US::004/035424 International Patent Classification (IPC) or both national classification and IPC A61J1/03, A61M15/00, B65D75/36, B65B5/10 Applicant ORIEL THERAPEUTICS, INC. This opinion contains indications relating to the following items: 1. Basis of the opinion Box No. I ☐ Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☑ Box No. III Lack of unity of invention Box No. iV Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement DOCKET Certain documents cited ☐ Box No. VI Certain defects in the international application Box No. VII ☐ Box No. VIII Certain observations on the international application **FURTHER ACTION** 2. Date If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Authorized Officer Name and mailing address of the ISA:

Zeinstra, H

Telephone No. +31 70 340-2824

European Patent Office - P.B. 5818 Patentiaan 2

Nt-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl

Fax: +31 70 340 - 3016

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US2004/035424

	Box N	o. I Basis of the opinion
1.	With re	gard to the language , this opinion has been established on the basis of the international application in guage in which it was filed, unless otherwise indicated under this item.
	lai	is opinion has been established on the basis of a translation from the original language into the following nguage , which is the language of a translation furnished for the purposes of international search nder Rules 12.3 and 23.1(b)).
2.	With re	egard to any nucleotide and/or amino acid sequence disclosed in the international application and sary to the claimed invention, this opinion has been established on the basis of:
	a. type	of material:
		a sequence listing
		table(s) related to the sequence listing
	b. forn	nat of material:
		in written format
		in computer readable form
	c. time	of filing/furnishing:
		contained in the international application as filed.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority for the purposes of search.
3.	h c	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto as been filed or furnished, the required statements that the information in the subsequent or additional opies is identical to that in the application as filed or does not go beyond the application as filed, as ppropriate, were furnished.

4. Additional comments:

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

	Box No. ill Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
The obv	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:					
	the entire international application	on,				
\boxtimes	claims Nos. 3, 4, 6, 8, 10, 11, 18	3-24,	26-74			
bec	ause:					
	the said international application does not require an international	n, or al pre	the said claims Nos. relate to the following subject matter which liminary examination (specify):			
Ľ	the description, claims or drawin unclear that no meaningful opin	ngs (ion c	indicate particular elements below) or said claims Nos. are so could be formed (specify):			
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.					
\boxtimes	no international search report has been established for the whole application or for said claims Nos. 3, 4, 6, 8, 10, 11, 18-24, 26-74					
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:					
	the written form		has not been furnished			
			does not comply with the standard			
	the computer readable form		has not been furnished			
			does not comply with the standard			
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.					
	☐ See separate sheet for further details					

	Box	No. IV	Lack of unity of in	nvention				
1.	\boxtimes	In resp	onse to the invitation	(Form PC	T/ISA/206)	to pay additional fees, th	e applicant has:	
			paid additional fees.					
			paid additional fees	under pro	test.			
		\boxtimes	not paid additional fe	es.				
		the app	olicant to pay addition	ial fees.		y of invention is not comp		
3.	Thi	s Authoi	rity considers that the	requirem	ent of unity	of invention in accordance	ce with Rule 13.1, 13.2	end 13.3 is
		complie	d with plied with for the follo	owing reas	sons:			
				,				
	_		eparate sheet	on estab	lished in re	spect of the following par	ts of the international a	pplication:
4.				sen estab	101100 11110	opool of the tenering pair		
	□ all parts.							
	\boxtimes	the part	s relating to claims N	los. 1, 2, 4	1, 5, 7, 9, 1	2-17, 25		
-	Bo	x No. V	Reasoned stater	nent unde	er Rule 43. explanation	bis.1(a)(i) with regard to as supporting such state	novelty, inventive steement	ep or
1.		atement					•	
	No	ovelty (N)	Yes: No:	Claims Claims	1,2,4,5,7,9,12-17,25		
	lnv	ventive s	step (IS)	Yes: No:	Claims Claims	1,2,4,5,7,9,12-17,25		
	Inc	dustrial a	applicability (IA)	Yes: No:	Claims Claims	1,2,4,5,7,9,12-17,25		

2. Citations and explanations

see separate sheet

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

-50 --

Re Item IV.

1 The separate inventions/groups of inventions are:

1, 2, 4, 5, 7, 9, 12-17, 25: None

3, 4, 6, 8, 21:

A drug containment system wherein the tab members have a loop member (Problem: to avoid parts of the sealant material to be inhale by the patient)

10, 11, 18

A drug containment system wherein each tab is associated with a plurality of drug compartments

(Problem: to allow combination inhalation dry powder drug delivery in operative position in an inhaler)

19, 20, 22-24

A drug containment system wherein the plurality of drug compartments is at least 60 (Problem: to permit the user to have a longer journey with only one package)

26-50, 65-74

A dry powder inhaler with vibrator, and method of operating (Problem: to prevent agglomeration fo the powder)

51-64

A multi-dose dry powder inhaler with a hook member (Problem: to facilitate the opening of the blister)

- 2 They are not so linked as to form a single general inventive concept (Rule 13.1 PCT) for the following reasons:
- 2.1 The document US-A-5622166 (of which the document US-A-6029663 cited in the description is a continuation) cited in the search report discloses a dry powder inhaler

delivery system comprising essentially:

- a multi-dose package,
- a support member,
- a drug compartment,
- a sealant material,
- a tab member,
- an elongate chamber,
- an air inlet port,
- a mouthpiece.

Over this prior art, no special technical feature (in the meaning of Rule 13.2 PCT) remains in claims 1, 2, 4, 5, 7, 9, 12-17, 25 of the application.

2.2 Over this prior art, the potential special technical features (in the meaning of Rule 13.2 of the PCT) in the independent and dependent claims are:

Claims 1, 2, 4, 5, 7, 9, 12-17, 25: none,

Claims 3, 4, 6, 8, 21: A drug containment system wherein the tab members have a loop member,

Claims 10, 11, 18: A drug containment system wherein each tab is associated with a plurality of drug compartments,

Claims 19, 20, 22-24: A drug containment system wherein the plurality of drug compartments is at least 60,

Claims 26-50, 65-74: A dry powder inhaler with vibrator, and method of operating, Claims 51-64: A multi-dose dry powder inhaler with a hook member.

- 2.3 Accordingly, it appears that a posteriori, the above listed claims do not satisfy the requirement of unity of invention.
- 2.4 Furthermore, it is pointed out that also when considering the effects associated with the different groups of claims, no single general inventive concept exists between said different groups. Since there exists no other common special technical feature within the meaning of Rule 13.2 PCT, no technical relationship between the different groups of claims can be seen.

Re Item V.

- Reference is made to the following document:
 D1: US 5 622 166 A (EISELE ET AL) 22 April 1997 (1997-04-22)
- 4 INDEPENDENT CLAIM 1
- 4.1 The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claim 1 is not new in the sense of Article 33(2) PCT.

 Document D1 (see column 2, line 55 column 3, line 42, figures 1-7) discloses (the references in parentheses applying to this document):

 A multi-dose drug containment system package adapted for use in an inhaler (20), comprising:
 a support member (46) comprising a plurality of spaced apart drug compartments (36), each drug compartment (36) having a sealant material (56) detachably sealed
 - thereto; and a plurality of spaced apart tab members (48), a respective tab member (48) attached to a portion of sealant material (56) that extends over one or more drug compartments (36), wherein a respective tab member (48) is operatively associated with at least one drug compartment (36) so that, in operation, the respective tab member (48) is configured to be grasped, such grasping causing the associated sealant material (56) to pull away from at least one drug compartment (48) to release
- DEPENDENT CLAIMS 2, 4, 5, 7, 9, 12-17, 25

 Dependent claims 2, 4, 5, 7, 9, 12-17, 25 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of novelty (Article 33(2) PCT).

a drug held therein.

- 5.1 In particular, the features of claims 2, 4, 5, 7, 9, 12-17, 25 are disclosed in combination with the features of claim 1 in D1 (see column 2, line 55 column 3, line 42, figures 1-7).
- The system package described in the claims is industrially manufacturable, and therefore meet the requirements of Article 33(4) PCT.

Re Item VII.

- Independent claims 1, 15 and 16 are not in the two-part form in accordance with Rule 6.3(b) PCT, which in the present case would be appropriate, with those features known in combination from the prior art (document D1) being placed in the preamble (Rule 6.3(b)(i) PCT) and with the remaining features being included in the characterising part (Rule 6.3(b)(ii) PCT).
- The features of the claims are not provided with reference signs placed in parentheses (Rule 6.2(b) PCT).
- Ontrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this document identified therein.